Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trialBianca Weinstock‐Guttman, Jerry S. Wolinsky, Mark S. Freedman et al.|Multiple Sclerosis Journal|2021Cited by 23